A new publication involving teriparatide was released on August 19, 2026. The article, titled "Restoring skeletal remodeling in antiresorptive-treated patients: clinical outcomes of teriparatide in medication-related osteonecrosis of the jaw," appeared in Osteoporosis International, a journal established through cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
The publication addresses clinical outcomes of teriparatide in patients with medication-related osteonecrosis of the jaw, a condition associated with antiresorptive treatment. No specific findings, results, or efficacy data from the publication have been detailed beyond its title and journal placement.
Teriparatide remains an approved compound. This item reports only that the publication has been indexed and made available, as listed on PubMed under ID 42616119. Readers interested in the full scope of the study, including methodology and any reported outcomes, are directed to consult the original article through the provided source link.
For general background on teriparatide, including its approved uses and regulatory status, see the compound overview.